Publication
In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer.
Authors not recorded
Anticancer Res2015PMID 25550549stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerMalignant Head and Neck Neoplasmcivic_curation1.00
- drugAlpelisibcivic_curation1.00
- genePIK3CAcivic_curation1.00
- variantPIK3CA H1047Rcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 25550549
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| PIK3CA H1047R1 | ||||||||
| Alpelisib | Malignant Head and Neck NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 1 | accepted | EID1401In a panel of head and neck cancer cell lines, 2 lines containing the PIK3CA mutation H1047R (Detroit562 and SNU-1076) were more sensitive to growth inhibition (IC50 1.10 and 6.82) by the PI3Kalpha sp… (full text at CIViC) PMID 25550549 · Keam et al., 2015 · Open in CIViC | civic |